Effective January 1, 2017 - New permanent J-code for ONIVYDE: J9205, injection, irinotecan liposome, 1 mg This information is presented for informational purposes only and is not intended to provide reimbursement or legal advice.

FOR US HEALTHCARE PROFESSIONALS ONLY Call Us at (844) 441-MACK (6225)

Expert Videos & Resources

The following video chapters were previously recorded as part of a live, national broadcast event. Dr George Kim and Dr John Marshall review the results of the NAPOLI-1 Phase 3 trial that supported the approval of ONIVYDE® (irinotecan liposome injection) and share details about the key efficacy, safety, and recommended dosing information. Dr Kim and Dr Marshall will also present a patient case study and discuss the potential integration of this therapy into clinical practice.

In the Resources section below these videos, please review the published NAPOLI-1 study in The Lancet. If you do not have individual or institutional access to this journal, please contact us for a copy of the article.

1. Introducing ONIVYDE® (irinotecan liposome injection)

Dr Khalid Mamlouk of Merrimack Pharmaceuticals welcomes our experts. Dr George Kim—Consultant with 21st Century Oncology—discusses the indication, structure, and mechanism of delivery of ONIVYDE, an encapsulation of irinotecan in a long-circulating liposome.

RESOURCES

INDICATION AND IMPORTANT SAFETY INFORMATION

**National Comprehensive Cancer Network® (NCCN®).

EXPAND

INDICATION AND IMPORTANT
SAFETY INFORMATION